Inozyme Pharma Dirección
Dirección controles de criterios 2/4
El CEO de Inozyme Pharma es Doug Treco , nombrado en Apr 2023, tiene una permanencia de 1.58 años. compensación anual total es $5.30M, compuesta por 7.1% salario y 92.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.035% de las acciones de la empresa, por valor de $62.87K. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 6.6 años, respectivamente.
Información clave
Doug Treco
Chief Executive Officer (CEO)
US$5.3m
Compensación total
| Porcentaje del salario del CEO | 7.1% |
| Permanencia del CEO | 1.6yrs |
| Participación del CEO | 0.03% |
| Permanencia media de la dirección | 2.5yrs |
| Promedio de permanencia en la Junta Directiva | 6.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Nov 17
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Aug 03Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
Jul 30Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Mar 08Inozyme Pharma GAAP EPS of -$0.38
Aug 15Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency
Jul 19Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
May 22Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency
May 07We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely
Feb 06
Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder
Jan 04Inozyme Pharma (INZY) Investor Presentation - Slideshow
Dec 03Inozyme Pharma EPS misses by $1.02
Nov 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$96m |
| Jun 30 2024 | n/a | n/a | -US$89m |
| Mar 31 2024 | n/a | n/a | -US$77m |
| Dec 31 2023 | US$5m | US$375k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$68m |
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$68m |
| Dec 31 2022 | US$106k | n/a | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$67m |
| Jun 30 2022 | n/a | n/a | -US$65m |
| Mar 31 2022 | n/a | n/a | -US$62m |
| Dec 31 2021 | US$188k | n/a | -US$57m |
| Sep 30 2021 | n/a | n/a | -US$49m |
| Jun 30 2021 | n/a | n/a | -US$63m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$339k | n/a | -US$56m |
Compensación vs. Mercado: La compensación total de Doug($USD5.30M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.46M).
Compensación vs. Ingresos: La compensación de Doug ha aumentado mientras la empresa no es rentable.
CEO
Doug Treco (66 yo)
1.6yrs
Permanencia
US$5,299,476
Compensación
Dr. Douglas A. Treco, also known as Doug, Ph D., is an Advisor at LSV Capital Management LLC. Earlier he was a Scientific Advisor at the firm.He was Chief Executive Officer of Alchemab Therapeutics from A...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman | 1.6yrs | US$5.30m | 0.035% $ 62.9k | |
| Co-Founder | no data | US$1.80m | 0.42% $ 749.4k | |
| Senior VP | 2.7yrs | US$1.03m | 0.047% $ 85.4k | |
| Senior VP & COO | 1.6yrs | US$1.55m | 0.0076% $ 13.8k | |
| Co-Founder | no data | sin datos | sin datos | |
| Senior VP & Chief Technical Operations Officer | 2.7yrs | sin datos | sin datos | |
| Senior VP | 1.8yrs | sin datos | sin datos | |
| Director of Investor Relations | no data | sin datos | sin datos | |
| Senior VP & Chief People Officer | 3.3yrs | sin datos | sin datos | |
| Chairman of Scientific Advisory Board & Senior VP | no data | sin datos | sin datos | |
| Consultant | 2.7yrs | sin datos | sin datos | |
| Senior VP & Chief Medical Officer | 2.4yrs | sin datos | sin datos |
2.5yrs
Permanencia media
58.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de INZY se considera experimentado (2.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Chairman | 4.5yrs | US$5.30m | 0.035% $ 62.9k | |
| Co-Founder | 9.2yrs | US$1.80m | 0.42% $ 749.4k | |
| Co-Founder | no data | sin datos | sin datos | |
| Chairman of Scientific Advisory Board & Senior VP | no data | sin datos | sin datos | |
| Independent Director | 7.2yrs | US$129.65k | 0% $ 0 | |
| Lead independent director | 7.8yrs | US$130.27k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | US$135.00k | sin datos | |
| Independent Director | 7.8yrs | US$116.15k | 0% $ 0 | |
| Independent Director | 6yrs | US$112.15k | 0% $ 0 | |
| Independent Director | 5.7yrs | US$114.65k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$122.15k | 0% $ 0 | |
| Chairperson of Clinical Advisory Board | no data | sin datos | sin datos |
6.6yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de INZY se considera experimentada (6.6 años de antigüedad promedio).